MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
29 Luglio 2024 - 1:00PM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or
“MindMed”), a clinical-stage biopharmaceutical company developing
novel product candidates to treat brain health disorders, today
announced the appointment of Stephanie Fagan, effective today, as
Chief Corporate Affairs Officer. Ms. Fagan will serve as a member
of the executive team and will oversee public affairs and corporate
communications for the Company.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240729857388/en/
Stephanie Fagan, Chief Corporate Affairs
Officer of MindMed (Photo: Business Wire)
“I want to welcome Stephanie to the MindMed team. Stephanie’s
track record leading and executing successful multi-stakeholder
strategies will be critical as we advance MM120 into pivotal trials
and ultimately to the market. This new role underscores our
commitment to deepening engagement with our partners and
communities as we continue to build MindMed into a leading
biopharmaceutical company developing novel products to treat brain
health disorders,” said Rob Barrow, Chief Executive Officer of
MindMed.
“MindMed is pioneering the future of brain health with potential
groundbreaking treatments, and I am thrilled to join a company
dedicated to transforming patient outcomes in an area of immense
public health need,” said Stephanie Fagan, MindMed’s newly
appointed Chief Corporate Affairs Officer. “I look forward to
collaborating with our team and engaging deeply with the
communities we serve to realize the full therapeutic potential of
MM120 for generalized anxiety disorder and to advance our
innovative pipeline of product candidates.”
Stephanie Fagan brings over 20 years of experience as an
executive in the healthcare industry leading strategies that drive
organizational success through innovative communication and
stakeholder engagement. Ms. Fagan joins MindMed from Agenus where
she was Chief Communications Officer and before that, she was
Senior Vice President, Corporate Affairs and Chief Communications
Officer at Acadia Pharmaceuticals, overseeing all internal and
external communications. She joined Acadia from bluebird bio, Inc.,
where she was Senior Vice President, Corporate Communications, and
built the first communications function as the company transitioned
from a clinical to a commercial-stage company. Prior to bluebird,
she led corporate affairs and communications functions at Alexion,
Shire and West Health. Over the course of her career, Ms. Fagan has
served in positions of increasing influence and impact in the
healthcare industry, including roles at Johnson & Johnson,
Allergan, Pharmacia, Inc. (now Pfizer), and Boston Scientific
Corporation.
Ms. Fagan earned a Master of Science in Mass Communications from
Boston University and a Bachelor of Arts in English from Wheaton
College.
Inducement Grants under Nasdaq Listing Rule
5635(c)(4)
In connection with her appointment as Chief Corporate Affairs
Officer, MindMed granted Ms. Fagan inducement awards consisting of
(a) 60,000 time-based restricted stock units ("RSUs") and (b) an
option to purchase an aggregate of 110,000 common shares of the
Company (the "Option"), each with an effective grant date of July
29, 2024. The RSUs will vest over four years, with 25% of the
shares vesting on the first anniversary of Ms. Fagan’s start date,
and the remaining 75% vesting in substantially equal increments
monthly over the next three-year period thereafter, subject to her
continuous employment. The Option has an exercise price equal to
the closing price of MindMed’s common shares on July 26, 2024, the
last trading day on which MindMed’s common shares traded prior to
the date of the grant, and will vest four-year period with 25%
vesting on the first anniversary and the remaining 75% vesting in
substantially equal quarterly increments over the next three-year
period thereafter, subject to her continued employment.
The inducement awards to Ms. Fagan were granted as a material
inducement to her employment and were approved by MindMed's
Compensation Committee on July 18, 2024, in accordance with Rule
5635(c)(4) of The NASDAQ Stock Market LLC. The awards were granted
outside MindMed's equity incentive plans.
About MindMed
MindMed is a clinical-stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders. MindMed trades on NASDAQ under the symbol MNMD.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute “forward-looking information” within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “will”, “may”, “should”, “could”,
“intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”,
“potential” or “continue”, or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, statements regarding the potential
benefits of the Company’s product candidates. There can be no
guarantees regarding the timing or results of the potential Phase 3
clinical trials for MM120 for the treatment of GAD or that,
following any such trials, MM120 will receive the necessary
regulatory approvals. There are numerous risks and uncertainties
that could cause actual results and the Company’s plans and
objectives to differ materially from those expressed in the
forward-looking information, including its history of negative cash
flows; limited operating history; incurrence of future losses;
availability of additional capital; lack of product revenue;
compliance with laws and regulations; difficulty associated with
research and development; risks associated with clinical trials or
studies; heightened regulatory scrutiny; early stage product
development; clinical trial risks; regulatory approval processes;
novelty of the psychedelic inspired medicines industry; as well as
those risk factors discussed or referred to herein and the risks
described in the Company’s Annual Report on Form 10-K for the
fiscal year ended December 31, 2023, under headings such as
“Special Note Regarding Forward-Looking Statements,” “Risk Factors”
and “Management’s Discussion and Analysis of Financial Condition
and Results of Operations,” and other filings and furnishings made
by the Company with the securities regulatory authorities in all
provinces and territories of Canada which are available under the
Company’s profile on SEDAR+ at www.sedarplus.ca and with the U.S.
Securities and Exchange Commission on EDGAR at www.sec.gov. Except
as required by law, the Company undertakes no duty or obligation to
update any forward-looking statements contained in this release as
a result of new information, future events, changes in expectations
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240729857388/en/
For Media: media@mindmed.co For Investors:
ir@mindmed.co
Grafico Azioni Mind Medicine MindMed (NASDAQ:MNMD)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Mind Medicine MindMed (NASDAQ:MNMD)
Storico
Da Dic 2023 a Dic 2024
